Eribulin mesylate

(Halaven®)

Halaven®

Drug updated on 10/23/2023

Dosage FormInjection (intravenous: 1 mg per 2 mL (0.5 mg per mL))
Drug ClassMicrotubule inhibitor
Ongoing and
Completed Studies
ClinicalTrials.gov

Indication

  • For the treatment of metastatic breast cancer who have previously received at least two chemotherapeutic regimens for the treatment of metastatic disease. Prior therapy should have included an anthracycline and a taxane in either the adjuvant or metastatic setting
  • For the treatment of unresectable or metastatic liposarcoma who have received a prior anthracycline-containing regimen.

Product Monograph / Prescribing Information

Document TitleYearSource
Halaven (eribulin mesylate) Prescribing Information.2022Eisai Inc. Nutley, NJ

Systematic Reviews / Meta-Analyses